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Abstract
Cyclophilins (Cyps), the intracellular receptors for Cyclosporine A (CsA), are responsible for peptidyl-prolyl cis-trans
isomerisation and for chaperoning several membrane proteins. Those functions are inhibited upon CsA binding. Albeit its
great benefits as immunosuppressant, the use of CsA has been limited by undesirable nephrotoxic effects, including sodium
retention, hypertension, hyperkalemia, interstial fibrosis and progressive renal failure in transplant recipients. In this report,
we focused on the identification of novel CypB-interacting proteins to understand the role of CypB in kidney function and,
in turn, to gain further insight into the molecular mechanisms of CsA-induced toxicity. By means of yeast two-hybrid screens
with human kidney cDNA, we discovered a novel interaction between CypB and the membrane Na/K-ATPase b1 subunit
protein (Na/K-b1) that was confirmed by pull-down, co-immunoprecipitation and confocal microscopy, in proximal tubule-
derived HK-2 cells. The Na/K-ATPase pump, a key plasma membrane transporter, is responsible for maintenance of electrical
Na+ and K+ gradients across the membrane. We showed that CypB silencing produced similar effects on Na/K-ATPase
activity than CsA treatment in HK-2 cells. It was also observed an enrichment of both alpha and beta subunits in the ER,
what suggested a possible failure on the maturation and routing of the pump from this compartment towards the plasma
membrane. These data indicate that CypB through its interaction with Na/K-b1 might regulate maturation and trafficking of
the pump through the secretory pathway, offering new insights into the relationship between cyclophilins and the
nephrotoxic effects of CsA.
Citation: Sun ˜e ´ G, Sarro ´ E, Puigmule ´ M, Lo ´pez-Hellı ´n J, Zufferey M, et al. (2010) Cyclophilin B Interacts with Sodium-Potassium ATPase and Is Required for Pump
Activity in Proximal Tubule Cells of the Kidney. PLoS ONE 5(11): e13930. doi:10.1371/journal.pone.0013930
Editor: Niels Olsen Saraiva Ca ˆmara, Universidade de Sao Paulo, Brazil
Received July 12, 2010; Accepted October 12, 2010; Published November 10, 2010
Copyright:  2010 Sun ˜e ´ et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants FIS PI081351 (Instituto de Salud Carlos III, Ministerio de Ciencia e Innovacion) SAF2005-05167 from Ministerio de
Educacion y Ciencia (MEC), grant 002230 from Fundacio La Marato de TV3, from Fundacion Renal In ˜igo Alvarez de Toledo (FRIAT), Fundacion SENEFRO y
Fundacion Mutua Madrilen ˜a to Dr. Anna Meseguer (AM). Funding was also provided by grants from the Swiss National Science Foundation and the National
Institute of Allergy and Infectious Diseases (USA) to Dr. Jeremy Luban. Guillermo Sun ˜e ´ was a predoctoral recipient fellow (FPI) from the CIRIT (Consell
Interdepartamental de Recerca i Innovacio ´ Tecnolo `gica). Anna Meseguer’s research group holds the Quality Mention from the Generalitat de Catalunya (2009SGR).
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: ameseguer@ir.vhebron.net
Introduction
Cyclosporine A (CsA) is a potent immunosuppressive cyclic
undecapeptide mainly used to prevent graft rejection after
transplant surgery [1]. It has changed the outcomes of transplan-
tation and autoimmune diseases, although with the drawback of
significant nephrotoxicity [2]. CsA nephrotoxic effects include a
reduction in glomerular filtration rate by increasing arteriolar
vasoconstriction and renal vascular resistance, microvascular
arteriolopathy, interstitial fibrosis, and vacuolization of proximal
tubule cells [3,4]. Experimental models of CsA nephrotoxicity in
rats, in which glomerular hemodynamics were analyzed by renal
micropuncture techniques, revealed that CsA administration is
associated with afferent and efferent arteriolar vasoconstriction,
with predominating preglomerular vasoconstriction that results in
a significant reduction of renal plasma flow. A reduction of the
ultrafiltration coefficient has also been observed. The decrease in
these two hemodynamic variables lead to a significant reduction of
the single-nephron glomerular filtration rate and thus renal
dysfunction [3]. Hyperkalemia and metabolic acidosis have been
reported as negative side effects, as well. Studies in rats showed a
distal tubular acidification defect and a significant reduction in
sodium and potassium urinary excretion by intraperitoneal
administration of CsA [5,6]. The molecular mechanisms under-
lying such effects have not been completely uncovered. Cyclophi-
lins, first discovered as the intracellular receptors of CsA, are
conserved and ubiquitous enzymes that exhibit peptidyl prolyl cis-
trans isomerases (PPIases) activity and are involved in folding and
repair of proteins, as well as, acting as chaperones in both
prokaryotes and eukaryotes [7]. There are more than ten subtypes
of CyPs in mammals, distributed in different subcellular
compartments, that function in numerous cellular processes,
including transcriptional regulation, immune response, protein
secretion, and mitochondrial function [7–9]. CypA, the first
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e13930characterized cytosolic isoform considered as the major target for
CsA [10] has been located in the cytosol. CypB, the second
identified member of the family, is distinguished from CypA by the
presence of an endoplasmic reticulum-directed signal sequence
[11]. We hypothesized that identification of Cyp-interacting
proteins in kidney could be relevant to understand CsA
nephrotoxicity at the molecular level and, eventually, these
proteins might become therapeutical targets to avoid toxicity
while maintaining the drug’s immunosupresive effects in CsA-
treated patients. In this work, we describe that CypB interacts with
the Na/K-ATPase pump in human kidney and that this
cyclophilin is crucial for pump location and activity.
Results
Na/K-ATPase beta 1 subunit interacts with Cyclophilin B
The full length human CypB was screened against a human
kidney cDNA library in a yeast two-hybrid assay. Nine clones that
were effectively interacting with the CypB protein to support the
permissive growth of yeast cells in Trp
- Ade
- His
- Leu
- selective
media, became further selected in 10 mM AT (aminotriazol). One
of those clones was identified as the Na/K-ATPase beta subunit 1
(ATP1B1, GenBankTM accession number NM_001677). Fig. 1A
shows the interaction between Na/K-b1 and CypB, as well as a
positive control for protein interaction involving P53 and SV40
large T antigen proteins (Control +), and a negative control
involving the non-interacting lamin C with the SV40 large T
antigen (Control -). The plasmid for the Na/K-ATPase beta fusion
was isolated from yeast after the primary screen and retested in
fresh yeast (not shown).
GST-pull down and co-immunoprecipitation assays were
performed to further confirm the CypB-Na/K-b1 interaction.
Sepharose 4B conjugated GST and GST-CypB fusion proteins
were incubated with COS-7 cell lysates expressing transiently
transfected Na/K-b1. After extensive washing in GST buffer, the
glutathione beads were boiled in sample buffer, and the
supernatant analyzed by SDS-polyacrylamide gel electrophoresis.
To recognize the CypB-interacting protein, western blots against
Na/K-b1 were performed (Fig. 1B). Results shown in this figure
demonstrate that the binding capacity of GST-CypB for Na/K-b1
depends on the CypB moiety since GST alone is unable to bind
Na/K-b1. We next performed co-immunoprecipiation assays on
HK-2 crude extracts as a demonstration of endogenous interaction
and detected CypB in anti-Na/K-b1 immunoprecipitates (Fig. 1C).
We also detected the beta-interacting alpha subunit in CypB
immunoprecipitates, as expected (Fig. 1D). This was confirmed by
reverse co-immunoprecipitation (Fig. 1E). Altogether, these results
demonstrated for the first time that CypB interacts with the Na/K-
b1, and that the alpha subunit is also co-immunoprecipitated as a
part of the complex.
The distribution pattern of endogenous CypB and Na/K-b1i n
human kidney derived tubular cells (HK-2) was studied by
Figure 1. Interaction between CypB and Na/K-ATPase beta and alfa subunits. A: Yeast two hybrid assay. CDNA for CypB was cloned in
frame into the yeast expression vector (pGBKT7) that harbours the GAL4 activation domain. The recombinant plasmids plus Human Kidney
Matchmaker cDNA Library were co-transformed into AH109 yeast strain. The co-transformed cells were selected on Ade-/Leu-/His-/Trp-, 10 mM
Aminotriazol dropout plates to monitor for growth. The positive control represents co-transformation of p53 and T-antigen in two-hybrid expression
vectors, pGBKT7-P53 and pGADT7 (BD Biosciences, Clontech), respectively. B: GST-pull-down assays. CypB was fused in frame with the GST gene. GST
and GST-HCypB products were immobilized on Sepharose 4B and incubated with COS-7 cells lysates expressing Na/K-b1 (pCMV-HA-Na/K). The bound
proteins were analyzed by immunoblotting with anti-Na/K-b1 rabbit polyclonal antibody. C–E: Co-Immunoprecipitation assays. HK-2 lysates were
immunoprecipitated with mouse monoclonal antibodies against Na/K-b1 or Na/K-a1 and rabbit polyclonal antibody against CypB. The
immunoprecipitates were subjected to Western blotting analyses, as indicated in the figure. As control, ChromePure mouse IgG and ChromePure
rabbit IgG were used. Figures 1B to 1E are representative of at least three independent experiments.
doi:10.1371/journal.pone.0013930.g001
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compatible with the endoplasmic reticulum (ER) and the plasma
membrane (Fig. 2). Our results indicate that CypB and Na/K-b1
mainly co-locate in the ER (See inset for enlargement). Such an
interaction between the Na/K-b1 and CypB may occur
transiently or only along certain steps of the sorting process
according to data presented in Fig. 2.
Effects of CsA treatment on activity, expression and
location of Na/K-b1 pump in HK-2 cells
Although it was previously described that CsA alters the activity
of the pump in the kidney [12], the underlying molecular
mechanisms were not elucidated. To further explore them, we
observed the effects of different doses of CsA (10 nM, 100 nM,
1 mM, and 10 mM) on Na/K-ATPase activity in HK-2 cells, after
24 h treatment. Na/K-ATPase levels were quantified by deter-
mining the p-Nitrophenylphosphate (p-NPPase) activity inhibited
by ouabain. Our results showed that deleterious effect of CsA on
Na/K-ATPase activity was time and dose-dependent. Decline of
activity was evident at 1 mM CsA with 50% of inhibition at 10 mM
after 24 h of treatment (Fig. 3A and 3B). Western blot assays
performed in crude lysates of CsA-treated cells showed similar
Na/K-b1 levels, at any CsA concentration tested, indicating that
CsA effects on pump activity were unrelated with changes on
protein content (Fig. 3C). By confocal microscopy, we observed an
intracellular location of Na/K-b1 in CsA-treated cells, rather than
the cell membrane distribution observed in vehicle-treated cells
(Fig. 3D). In these same conditions, CypB staining was less evident
(Fig. 3E). Western blot assays confirm a gradual CypB diminish-
ment in crude cell extracts (Fig. 3F) that became very prominent at
10 mM and a CypB enrichment in conditioned media (Fig. 3G)
detectable at the dose of 1 mM CsA. These results indicated that
the dose-dependent decrease of intracellular CypB levels after CsA
treatment, correlated with altered pump activity and Na/K-b1
location.
Na/K-ATPase location and activity in CypB silenced
human kidney cells (HK-2)
To further prove the involvement of CypB on Na/K-ATPase
location and activity, HK-2 cells were silenced for CypB using the
lentiviral system CypB-shRNA or Luc-shRNA (negative lentivirus
control). Expression of CypB in silenced cells was determined by
western-blot and compared with levels of actin-b, which was used
as loading control. Results in Fig. 4A clearly demonstrated that
CypB expression was fully inhibited in this lentiviral siRNA
silenced cell system. The Na/K-ATPase activity on interfered
CypB cells was similar to values observed in parental HK-2 cells
treated with doses of CsA that provoked the lost of intracellular
CypB. Cells silenced for CypA or luciferase showed no effects on
Na/K-ATPase activity (Fig. 4B).
The location of endogenous Na/K-b1 subunit in CypB-
shRNA silenced HK-2 cells (Fig. 5. Panel C) was observed and
compared with the effects produced by CsA-treatment in Luc-
shRNA HK-2 cells (Fig. 5. Panel B). In non-treated Luc-shRNA
HK-2 control cells, the Na/K-b1 subunit is located in the
plasma membrane (Fig. 5. Panel A, white arrows) and the
cytosol, following a pattern compatible with the ER, as shown by
CypB distribution (Fig. 5. Panel A, yellow arrows). In the
presence of CsA, the Na/K-b1 subunit shows a diffused location
(Fig. 5. Panel B), which is in accordance with effects in parental
non-modified HK-2 cells treated with CsA (See Fig. 3. Panels D–
G). In CypB-shRNA silenced HK-2 cells, Na/K-b1r e m a i n sa t
the ER and is not found in the plasma membrane (Fig. 5. Panel
C, yellow arrows). In conclusion, CsA treatment or CypB
silencing impair Na/K pump targeting to the plasma mem-
brane.
Figure 2. Co-localization experiments between CypB and Na/K-b1 in HK-2 cells. Immunocitochemistry assays using anti-CypB rabbit
polyclonal antibody and mouse monoclonal anti-Na/K-b1 antibodies were performed on HK-2 cells. Fluorescence labelling was visualized in a Leica
DM IRBE confocal microscope. See inset magnification for co-localization. Figures are representative of at least three independent experiments.
doi:10.1371/journal.pone.0013930.g002
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fractionation of CsA-treated or CypB-silenced HK-2 cells
To further assess the distribution of beta and alpha subunits in
CsA-treated or CypB silenced HK-2 cells, subcellular fracciona-
tion followed by western blot assays was performed. Results shown
in Fig. 6A indicate the distribution of representative subcellular
markers along a sucrose gradient (from 10% to 50% sucrose
concentration), obtained upon fractionation of Luc-shRNA HK-2
nuclei-free cell extracts. As shown, the Golgi marker syntaxin 6 is
mainly present in the 10% fraction; the ER marker calnexin is
more prominent in the 15% fraction; the plasma membrane
marker E-cadherin is mainly present in the 25% fraction, and the
ribosomal marker S6 more prominent at the heavier densities.
In those same samples, we observed that in control cells (sh Luc)
CypB is predominantly found in the 15% and 20% fractions. After
CsA treatment (sh Luc+CsA), CypB disappears from the 20%
fraction and appears in the 30% fraction. In CypB silenced cells
(sh CypB) the residual CypB is only present in the 20% fraction
(Fig. 6B). To correlate the location of CypB with pump subunits,
these same membranes were rehybridized with specific antibodies
against alpha and beta subunits. In non-treated cells, the beta
subunit is mainly distributed into the 15%, 20%, 25% and 30%
fractions. Upon CsA treatment, and also after CypB silencing, the
Na/K-b1 diminishes in the 20%, 25% and 30% fractions in
relation to the 15% fraction that appears relatively enriched
(Fig. 6B), following the same pattern than the ER marker calnexin.
The alpha subunit is mainly located in the 20% fraction in control
cells. After CsA treatment, Na/K-a1 shifts from the 20% to the
15% and 30% fractions, paralleling CypB distribution under this
treatment. In CypB silenced cells, the alpha subunit follows a
similar location than the beta, remains in the 20% fraction and
becomes enriched in the 15% fraction (Fig. 6B).
Discussion
Cyclophilins, first discovered as the intracellular receptors of the
immunossupressant CsA, facilitate protein folding via their PPIase
activity and contribute to the maturation of several proteins
[13,14]. A second but potentially more important role for
cyclophilins is as chaperone for protein trafficking and macromo-
lecular assembly. Among cyclophilins, CypB is targeted to the
secretory pathway via an ER signal sequence. CypB accumulates
both in the ER and in complexes on the plasma membrane and is
specifically mobilized by CsA that promotes its secretion into the
medium [15]. It was postulated a role for CypB as a chaperone to
proteins destined for the plasma membrane, rather than solely as a
proline isomerase functioning within the ER. This concept has
been further reinforced, since CypB has been found to be part of
Figure 3. Effects of CsA on Na/K-ATPase in HK-2 cells. A–B. Dose- and time-response effects of CsA on Na/K-ATPase activity. CsA inhibited Na/
K-ATPase activity at concentrations 10 mM (A). Time course inhibition of Na/K-ATPase activity after 2 h, 4 h, 10 h and 24 h, at 10 mM CsA (B). C: Na/K-
b1 stady-state levels after CsA treatment. Effects of different doses of CsA on Na/K-b1 protein expression levels. b-actin was used as a loading control.
D–E: Effects of CsA on Na/K-b1 and CypB localization. Immunocitochemistry assays using anti-CypB and anti-Na/K-b1 rabbit polyclonal antibodies
were performed on untreated (upper panel) and 10 mM CsA treated (lower panel) HK-2 cells. F–G: Effects of CsA on CypB expression. Intracellular (F)
and secreted (G) CypB levels in HK-2 cells treated with different doses of CsA. Ratios between CypB and actin signals in cell lysates have been
represented upon quantification. Figures are representative of at least three independent experiments.
doi:10.1371/journal.pone.0013930.g003
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ER stress [17].
In this report, we focused towards the identification of novel
CypB-binding proteins in kidney, in order to: i) learn more about
the endogenous functions of CypB and ii) unravel, in part, the
molecular mechanisms of CsA-induced kidney toxicity. We
identified an interaction between CypB and Na/K-b1 in human
kidney that was further confirmed in the proximal tubule derived
HK-2 cells, and in Na/K-b1 transfected COS-7 cells. Confocal
microscopy images revealed that the ER is the site for CypB and
Na/K-b1 transient interaction. Na/K-ATPase is an integral
basolateral membrane protein that participates in the maintenance
of cell volume and electrochemical gradients [18]. The functional
Na/K-ATPase is a heterodimeric ion pump that consists of one a
and one b subunit. The a subunit comprises the catalytic and
transport activities of the Na/K-ATPase, while the b subunit is
involved in the structural maturation and correct routing of the
functional heterodimeric Na/K-ATPase to the plasma membrane
[19]. In agreement with this, we have also found the b-interacting
a subunit in the CypB immunoprecipitates.
It is known that CsA inhibits Na/K-ATPase activity. This was
first described in rat kidney cortical homogenates [20] and in rat
nephron specific-segments [12]. Clearance studies showed that
intraperitoneal administration of CsA for one week causes a distal
tubular acidification defect in rats [5] and a significant reduction in
sodium and potassium excretion [6]. CsA-treated rats also have an
impaired ability to excrete a potassium load, despite serum
potassium concentrations that exceed 8.4 mEq/liter. CsA interferes
with potassium homeostasis in humans as well [21]. CsA-induced
hyperkalemia and decreased kaliuresis could be a consequence of
impaired potassium secretion and ultimately arising from CsA-
induced inhibition of pump activity in potassium secreting nephron
segments. Moreover, inhibition of Na/K-ATPase by CsA is very
relevant in the kidney since export of sodium from the cells provides
the driving force for several facilitated transporters which are
important for transepithelial transport and because translocation of
sodium from one side of the epithelium to the other creates an
osmotic gradient that drives absorption of water, which is crucial for
blood pressure control [22].
Albeit its relevance for kidney function, the exact molecular
mechanisms involved on the inhibition of the Na/K-ATPase by
CsA are not completely elucidated. In the rat nephron, it was
reported that CsA at 0.5 mM for 30 minutes inhibited Na/K-
ATPase activity in cortical collecting ducts (CCD), medullary thick
ascending limbs (mTAL) and outer medullary collecting ducts
from the outer stripe (OMCD0), by 35%, 53%, and 39%,
respectively [12]. Calcineurin involvement was later suggested
since FK506 and two other calcineurin inhibitors, significantly
reduced Na/K-ATPase activity in these nephron segments [23].
Remarkably, under these conditions (and up to 2 mM CsA for 60
minutes) Na/K-ATPase activity did not change in proximal tubule
S1, S2, and S3 subsegments [12,23]. Our results are in accordance
with these data since the proximal tubule derived HK-2 cells
required higher doses of CsA and longer treatment times for
maximal pump activity inhibition. Although it would be very
interesting to evaluate the effects of CsA in Na/K-ATPase
translocation and activity in the tubular distal cells as well, in
order to correlate with the hypercalemia induced by CsA
treatment in vivo, few cell lineages originated in human kidney
exist and, to our knowledge, no cell lines of distal origen are
currently available. Additionally, it has been reported that distal
epithelial cells from human kidney undergo transdifferentiation to
a more proximal phenotype in culture [24].
Since maximal pump impairment by CsA correlated with a
concomitant intracellular CypB diminishment (about 5-fold. See
Figure 3F) at doses much higher (10 mM) than the ones required
for calcineurin inhibition (at the nM range), we reasoned that
impairment of the pump relates with the drop of intracellular
CypB levels. The fact that CypB silencing, where calcineurin is not
inhibited, also reduces the Na/K-ATPase activity supports the
concept that in proximal tubule segments, CypB represents a key
molecule for pump function.
Figure 4. Na/K-ATPase activity decreases in CypB silenced human kidney cells (HK-2). A: HK-2 cells were silenced for CypB using
microRNA-based shRNA lentiviral vectors (mRNAi-CypB). Interference of the luciferase gene was used as control (ctl-luciferase). Western blot assays
show a complete lack of CypB in CypB silenced cells, even at saturating protein concentrations from cell lysates (20 mg). B: Na/K-ATPase activity
decreases in silenced CypB cells in a similar manner than 10 mM CsA treatment for 24 h does in HK-2 cells. Luciferase silenced HK-2 cells were used as
a control. CypA silencing in HK-2 cells does not have any effect on activity (not shown). Figures are representative of at least three independent
experiments.
doi:10.1371/journal.pone.0013930.g004
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mainly focused on post-translational mechanisms involving the
catalytic alpha subunit [25,26]. Phosphorylation of the alfa subunit
by PKC activation which can be, in turn, promoted by CsA [27],
represents the triggering signal for pump endocytosis into
endosomes via a clathrin vesicle-dependent mechanism [28]. To
the best of our knowledge, there is no data concerning the effects
of CsA on the regulatory Na/K-b1 subunit. It is well recognized
that the regulatory beta subunit acts as a chaperone that allows the
folding of newly synthetized alpha subunits, directs their targeting
from the ER to the appropriate plasma membrane domain and
stabilizes them within the membrane, being an absolute
requirement for pump and ATPase activities [29–31]. In this
report, we describe for the first time a novel interaction between
CypB and Na/K-b1 and demonstrate that CypB is required for
pump activity in proximal tubule cells. We showed that CypB
silencing produced similar effects on Na/K-ATPase activity than
CsA treatment resulting in enrichment of both alpha and beta
subunits in the ER, what suggests a failure on the maturation and
routing of the pump from this compartment towards the plasma
membrane. These data indicate that CypB through its interaction
with Na/K-b1 might regulate maturation and trafficking of the
pump through the secretory pathway. A similar mechanism has
been described for the Na/Ka1-ATPase subunit and the scaffold
ankyrin cytosolic protein. The presence of an ankyrin-binding
sequence in Na/Ka1-ATPase subunit facilitates its transport in the
secretory pathway in Madin-Darby canine kidney cells and in
other cultured cells [32].
According to the correlation observed between CsA doses,
intracellular CypB levels and pump activity, we propose that the
deleterious effects of CsA on tubular function have to do, at least in
part, with CypB secretion promotion. The involvement of CypB in
human disease has only been recently unravealed. For instance, it
has been described that CypB forms a complex with CRTAP
(cartilage-associated protein) and prolyl 3-hydroxylase 1 and that
mutations on any of these three proteins cause recessive form of
esteogenesis imperfecta and loss or decrease of type I collagen
prolyl 3-hydroxylation [33–35], which is a mechanism for
connective tissue disease. Expression of CypB has been associated
with malignant progression and regulation of genes implicated in
the progression of breast cancer [36]. CypB has also been
recognized as a partner of CD147. CD147 has been shown to
function as a signalling receptor for Cyclophilin A and B to
mediate chemotactic activity of cyclophilins towards a variety of
immune cells [37]. More recently, it has been reported that agents
targeting either CD147 or cyclophilin activity showed significant
Figure 5. Localization of Na/K-ATPase beta and CypB in silenced or CsA-treated HK-2 cells. Immunocitochemistry assays using anti-CypB
rabbit polyclonal antibody and mouse monoclonal anti-Na/K-b1 antibody were performed on luciferase silenced HK-2 control cells (ctl-luciferase)
(Panel A), 10 mM CsA treated ctl-luciferase cells, for 24 h (Panel B) and Cyp B silenced cells (Panel C). White arrows point to plasma membrane and
yellow arrows to endoplasmic reticulum localization. Fluorescence labelling was visualized in a Leica DM IRBE confocal microscope. Figures are
representative of at least three independent experiments.
doi:10.1371/journal.pone.0013930.g005
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tions may be a good target for new anti-inflammatory therapeutics
[38].
In the present report we claim an essential and novel role for
CypB in the maturation and trafficking of Na/Ka1-ATPase pump
through the secretory pathway. A series of important studies have
demonstrated non-pumping functions for the Na/K-ATPase that
include regulation of oncogenic transformation [39], epithelial to
mesenchymal cell transition [40], tight junction formation [41]
and control of the plasma membrane cholesterol distribution [42].
The novel interaction found between CypB and Na/K-b1 and the
importance of CypB as a Na/K-ATPase functional modulator
should be very relevant to further understand the role of CypB in
renal and extrarenal pathophysiology.
Materials and Methods
Cell lines, cultures and reagents
The proximal tubule epithelial derived cell line HK-2 (CRL-
2190) (immortalized by transduction with HPV-16) [43] was
obtained from the American Type Culture Collection (Manassas,
VA) and was cultured in Dulbecco’s modified Eagle’s medium
(DMEM)-Ham’s F12 (1:1 v/v); 60 nM sodium selenate; 5 mg/ml
transferrin; 2 mM glutamine; 5 mg/ml insulin; 50 nM dexameth-
asone; 5 nM triiodothyronine; 10 ng/ml epidermal growth factor;
20 mM D-glucose; 2% fetal calf serum; 20 mM HEPES, pH 7.4].
The COS-7 cell line (American Type Culture Collection,
Manassas, VA), an African green monkey kidney fibroblast-like
derived cell line, was maintained in DMEM supplemented with
10% fetal bovine serum (FBS), 1% L-glutamine, 1% nonessential
amino acids, penicillin (100 U/mL), and streptomycin (100 U/
mL) in 5% CO2. Media for cell culture and supplements were
obtained from Biological Industries (Kibbutz Beit, Haemek,
Israel). For CsA treatment, HK-2 cells were cultured into
100 mm plates up to confluence. CsA (Calbiochem) was added
to the plates at different doses (0 nM, 10 nM, 100 nM, 1 mM,
10 mM, 20 mM) at different times. The CsA doses used in this
study have been previously utilized for us and others to obtain a
nephrotoxic profile in vitro that would be relevant to the clinical
situation in patients, based on the CsA concentration range
Figure 6. Na/K pump subunits distribution upon subcellular fractionation of CsA-treated or CypB-silenced HK-2 cells. Sh Luc, Sh Luc
treated with CsA, and Sh CypB cells show different patterns of sedimentation on sucrose gradients of a and b Na/K ATPase and CypB. Cells treated or
untreated with CsA were harvested and loaded on sucrose gradients (10 to 50% w/v) as described in Methods. (A) Western Blot of fractions eluted
from sucrose gradient of Sh Luc cells probed against protein markers of specific cell compartments: Syntaxin-6 (Golgi), Calnexin (ER), E-cadherin
(Plasmatic Membrane) and S6 (Ribosomes). (B) Western Blot of fractions eluted from sucrose gradient of Sh Luc, Sh Luc + CsA, and Sh CypB cells
probed against a and b Na/K ATPase and CypB. Figures are representative of at least three independent experiments.
doi:10.1371/journal.pone.0013930.g006
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media from each situation were collected and stored for
immunoblotting, as described [44].
Yeast Two-Hybrid Assays
A yeast two-hybrid screening was performed using a human
kidney MATCHMAKER cDNA Library (BD Biosciences Clon-
tech. Palo Alto, CA). The complete human CypB (hCypB) cDNA
sequence was used as bait. The library was co-transformed with
the pGBKT7-GAL4 containing CypB, into AH109 competent
yeast cells following the manufacturer’s instructions. Positive and
negative controls provided with the library were used. As a positive
control, the pGBKT7-53 that corresponds to the fusion of GAL4
binding domain with p53 protein and the pGADT7-T that
expresses the GAL4 activating domain fused to the T antigen were
used. As a negative control, the vector pGBKT7-lam, containing
lamin C was used together with pGADT7-T.
Reverse transcription-PCR
For yeast two-hybrid assays, the hCypB cDNA was obtained
from fresh kidney surgical samples, corresponding to the normal
counterpart tissues of patients bearing a renal cancer tumor.
Samples were obtained at the time of surgery upon approval by
the Institutional Review Board, and informed consent from
patients before surgery. Total RNA was isolated using guanidine
thiocyanate as described elsewhere [47]. For cDNA synthesis and
PCR amplification, 0.5 mg of DNAse I treated total RNA was
reverse-transcribed and amplified using the Super Script One-Step
reverse transcription RT-PCR System (Invitrogen Life Technol-
ogies, Calsbard, Ca, USA) in a single step according to the
manufacturer’s instructions.
Plasmids
hCypB cDNA (GenBankTM accession number NM_000942)
was obtained by RT-PCR using specific primers: upper 59-
CATATGATGAAGGTGCTCCTTGCC-39, where the under-
lined sequence corresponds to the NdeI restriction site followed by
hCypB cDNA sequence at positions 1 to 18 from the translation
initiation site, and lower 59 CTGCACAAAGATGTCCCT-
GTGCCCTA-39, where underlined sequence corresponds to PstI
site and the rest to hCypB cDNA sequence, from positions 625 to
644 to the translation initiation site, which corresponds to positon
194 of the GenBank sequence. The cDNA was cloned into the
NdeI-PstI restriction endonuclease site of pGBKT7-GAL4
(Clontech) and used in yest two-hybrid assays, as stated above.
The pGEX-6P1-hCypB expression vector was constructed by
PCR amplification of hCypB cDNA using specific primers
(59GGATCCGCCGATGAGAAGAAGAAGGG-39 and 59CC-
CGGGAAAGATGTCCCTGTGCCCTA-39) and ligated into
the BamHI-SmaI restriction sites of pGEX-6P1 (Amersham) for
further expression and purification of recombinant GST-hCypB
fusion protein. The Na/K-b1 subunit, obtained from the yeast
two-hybrid library pray clone (in PCAT. BD Biosciences, clontech,
Palo Alto, CA), was subcloned into the BglII restriction
endonuclease site of pCMV-HA mammalian expression vector
(BD Biosciences, clontech, Palo Alto, CA) to get the pCMV- Na/
K-b1 -HA construct.
Expression and Purification of Recombinant Proteins
BL21 bacterial cells were transformed with constructs express-
ing GST and GST-hCypB proteins. Luria broth (500 ml)
containing 50 mg/ml ampicillin was inoculated with 5 ml of
bacteria and incubated in an orbital shaker at 37uC. Bacteria were
grown to A600=0.3, induced with 0.5 mM isopropyl-1-thio-b-D-
galactopyranoside, and shaken for 5 h at 37uC. The GST, and
GST-hCypB soluble proteins, obtained upon sonication, were
purified following the protocol for GSTrap FF 1 ml columns
(Amersham Biosciences). Protein concentration was not measured.
The expression level of the recombinant protein was evaluated in
comparison with endogenous proteins after electrophoresis on
10% polyacrylamide denaturing gels stained with Comassie Blue.
Transfections assays
Monolayers of COS-7 cells grown in 70% confluence were
transfected with 5 mg of pCMV-HA-Na/K-b using LipofectA-
MINE (Life Technologies Ltd.) according to the manufacturer’s
instructions. 24–48 h after transfection, cells were trypsinized.
After transfection, cells were lysed with a buffer containing 20 mM
Tris, 200 mM NaCl, 1 mM EDTA, 0.5 NP-40 and Protease
inhibitor Cocktail (SIGMA).
GST pull-down and co-immunoprecipitation assays
10 mg of GST and GST-CypB purified proteins (see above)
were incubated with 30 ml of Glutathione Sepharose 4B (GE
Healthcare) and 400 ml of enriched HA-Na/K-b1cell lysates (see
above), overnight at 4uC. Next day, beads were washed carefully
with lysis buffer three times. Then the beads were pelleted, mixed
with 15 ml SDS-sample dye mix, boiled for 5 min and subjected to
immunoblot analysis using specific anti-Na/K-b1 rabbit polyclon-
al antibody (H115: sc-25709, Santa Cruz biotechnology).
HK-2 cells were cultured into 100 mm plates up to confluence,
harvested and lysed with a buffer containing 20 mM Tris,
200 mM NaCl, 1 mM EDTA, 0.5 NP-40 and Protease inhibitor
Cocktail (SIGMA). Cell lysates were incubated overnight with
anti-CypB (PA1-027, Affinity Bioreagents), anti-Na/K-b1 (M17-
P5-F11, Mouse mAb #ab2873 ABCAM) and anti-Na/Ka1 (M8-
P1-A3, Mouse mAb #ab2872 ABCAM) primary antibodies,
respectively. ChromePure rabbit IgG and ChromePure mouse
IgG (Jackson ImmunoResearch) were used as control. Next day,
30 ml of protein G (SIGMA) was added into each tube and
incubated for 1 h at 4uC. The beads were washed three times with
lysis buffer and solubilized in 15 ml SDS sample buffer.
Western-Blotting
Samples were analyzed by SDS-12% polyacrylamide gel
electrophoresis (SDS-PAGE) under reducing conditions. Proteins
were transferred to a PVDF membrane (Schleicher&Schuell).
Blots were blocked for 1 h in PBS containing 5% non-dried milk
and incubated with the appropiate primary antibodies in the same
blocking buffer for 2 h at room temperature, anti-Na/K-b1
1:1000 (ABCAM), anti-Na/Ka1 1:1000 (See above) and 1:2000
anti cyclophilin B (See above). When indicated, anti-actin rabbit
polyclonal antibody (A5060, SIGMA) was included for protein
loading control. After incubation, blots were extensively washed
and incubated with horseradish peroxidase-conjugated mouse
anti-rabbit and anti-mouse secondary antibodies for 1 h at room
temperature. After washing, sensitive detection of bound antibody
was carried out using Amersham ECL Plus Western Blotting (GE
healthcare, UK), manufacturer’s protocol was applied.
Sucrose Gradient
HK-2 cells were harvested with 25 mM MES pH 6.5 buffer
containing 1% triton X-100 and protease inhibitors and
homogenized with a teflon Dounce homogenizer. The lysates
were centrifuged at 2000 rpm to pellet the nuclei and the
postnuclear supernatant was layered on the top of a discontinuous
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25 mM MES buffer (pH 6.5) containing 150 mM NaCl. Gradi-
ents were centrifuged 16 h at 260000 rcf on a Sorvall TH-641
rotor. Nine fractions corresponding to 10, 15, 20, 25, 30, 35, 40,
45 and 50% (w/v) sucrose were collected from the top of the
gradient, precipitated with TCA and washed with acetone. Pellets
were resuspended in Laemmli Buffer and subjected to western blot
analysis as described earlier. Specific anitibodies against Syntaxin6
1:1000 (Mouse mAb #S55420 Transduction Labs), Calnexin
1:1000 (Rabbit Polyclonal #SPA-860 STRESSGEN), E-cadherin
1:2500 (Mouse #610181 BD Biosciences) and S6 ribosomal
protein 1:1000 (5G10) Rabbit mAb #2217 Cell Signaling) were
used for identification of subcellular cell compartments in sucrose
gradient fractions.
Immunocytochemistry
HK-2 cells were allowed to spread on microscope cover glasses
(Marlenfeld GmbH & Co.KG) for 48 h, and further treated with
CsA (10 mM) for 24 h. Immunofluorescence staining of CypB and
Na/K-b1 was performed by washing slides twice in cold PBS and
fixed in cold 4% paraformaldehyde for 1 h followed by three 10-
min PBS washes. Aldehyde groups were blocked with 50 mM
NH2Cl for 30 min and washed for 5 min in PBS three times. Cells
were permeabilized with 0.1% triton X-100 for 10 min, followed
by washing with PBS twice and further blocking with 1% BSA in
PBS for 30 min. Slides were incubated for 90 min at room
temperature with 1:100 anti anti-Na/K-b1 rabbit polyclonal
antibody (Fig. 3) (H115: sc-25709, Santa Cruz biotechnology) or
with 1:100 anti-Na/K-b1 mouse monoclonal antibody (Fig. 2 and
5) (ABCAM) and 1:100 anti cyclophilin B rabbit polyclonal
antibody (PA1-027, Affinity Bioreagents). After washing, cells were
incubated with secondary antibodies (1:300 Anti-rabbit-TRITC,
T 5268, SIGMA; 1:500 Goat anti mouse Alexa Fluor 488
[A11029] and 1:500 Goat anti rabbit Alexa Fluor 568 [A11036]).
Slides were washed thrice with PBS followed by nuclei staining
with Hoechst 33342 (Sigma). Fluorescence labelling was visualized
in a confocal spectral FV 1000 Olympus microscope.
Na/K-ATPase activity assay
Na+-K+-ATPase activity was estimated on the basis of
measurement of p- nitrophenylphosphate (pNPP) hydrolysis.
Protein extracts from cells treated with 0 nM, 10 nM, 100 nM,
1 mM and 10 mM CsA for a 24 h period, or treated with 10 mM
CsA for 2 h, 4 h, 8 h, 10 h and 24 h, were incubated with 0.5 ml
of the buffer (50 mM Tris, 10 mM MgSO4, 5 mM EDTA,
90 mM KCl, pH 7.6) at 37uC for 30 minutes. Then, 0.5 ml of
buffer containing 12 mM p-nitrophenylphosphate with or without
ouabain were added to each sample. The samples were incubated
30 minutes at 37uC, the reaction was stopped by adding
trichloroacetic acid 30%. After for 5 min at 13200 rpm,
supernatant was collected and added into a spectrophotometer
cuvette containing 2 ml Tris 1 M, each sample was read at
410 nm absorbance.
shRNA transfections
MicroRNA-based shRNA lentiviral vectors were produced by
co-transfecting 293FT cells with transfer vectors encoding the
puromycin resistance gene and a shRNA targeting CypB or a
control non-targeting shRNA, the HIV-1 packaging plasmid
psPAX2, and a VSVg expression plasmid (pMD2.G) using
calcium precipitation. The transfection medium was exchanged
the following day and viral supernatant was harvested 48 hrs after
transfection, clarified by centrifugation (5 min at 2006 g), and
filtered through a 0.45 mm syringe filter (Sarstedt). Kidney cells
were transduced and placed in selection medium containing
5 mg/ml puromycin (Sigma) 72 hours after transduction. shRNA
targeting sequences: control non-targeting shRNA: ctctcgctt-
gggcgagagtaag. The hairpin sequence used for CypB was;
gccgggtgatctttggtctctt, which encompases nucleotides 149 to 170
from the translation initiation site of the hCypB sequence.
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